🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSELECT cost-effectiveness — looking for input Page 3

SELECT cost-effectiveness — looking for input

claudia_zurich Tue, Nov 11, 2025 at 1:22 PM 36 replies 1,506 viewsPage 3 of 8
JenPlateau
Member
234
890
Nov 2024
Missouri
Nov 17, 2025 at 10:47 PM#11
NurseAsh_DET said:
Denials are usually procedural rather than clinical, and the order that works reflects that.

This is exactly what I could not find anywhere else. Taking it to my next appointment.

Last edited: Nov 18, 2025 at 4:47 AM
25 0HPLC_Greg, LibrarianMeg, bri_stats and 22 others
Reply Quote Save Share Report
PedsEndoPhilly
Member
345
1,890
Jun 2024
Philadelphia, PA
Nov 18, 2025 at 12:39 PM#12

Adding the clinical framing, because it changes how the question reads.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.1 lbs/week average
Fasting glucose (finger stick): stable at 86 mg/dL
Blood pressure (home): 116/72 average
Resting heart rate: 66 bpm (down from 82)
Waist circumference: down 16 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

Last edited: Nov 18, 2025 at 5:39 PM
24 24wendy_avl, jason_paloalto, Dr.LeslieOBGYN and 21 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Nov 19, 2025 at 2:31 AM#13
lisa_labSD said:
Cardiac biomarkers and cardiovascular risk: my cardiologist ordered advanced cardiac labs given my family history.

This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

Worth separating that from cost and coverage, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

23 23AussieAnna, BethLabQueen, ChrisMacros and 20 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
stefan_berlin
Member
234
1,123
Oct 2024
Berlin, DE
Nov 19, 2025 at 4:23 PM#14
claudia_zurich said:
SELECT is the trial that changed the framing of this class, because it was an outcome trial rather than a weight trial: about a 20% relative reduction…

Vitamin deficiency cascade with cardiovascular risk: after 6+ months of reduced food intake, I developed a subtle but important pattern: low B12 → elevated homocysteine → increased cardiovascular risk marker.

The connection: B12 is a cofactor for homocysteine metabolism. Without adequate B12, homocysteine accumulates. This is ironic — taking a CV-protective medication while developing a CV risk factor from reduced nutrition.

Solution: comprehensive vitamin supplementation and regular lab monitoring. Don't let the medication's benefits be undermined by nutritional deficiencies.

22 22TirzTom, TrialTracker_MD, JennaRN and 19 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Nov 20, 2025 at 6:16 AM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

21 21PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 18 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register